BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition

Oncotarget
Sa Rang KimMichael Girardi

Abstract

While several systemic therapies are approved for cutaneous T cell lymphoma (CTCL), a non-Hodgkin lymphoma of skin-homing T cells that may involve lymph nodes and peripheral blood in advanced stages, relapses are common. Mutational analysis of CTCL cells has revealed frequent amplification of the MYC oncogene, and bromodomain and extraterminal (BET) protein inhibitors have been shown to repress MYC expression in various malignancies. Towards a potential novel therapy, we thus sought to examine the effect of BET inhibition on CTCL cells in vitro. Each of the four tested BET inhibitors (JQ1, ABBV-075, I-BET762, CPI-0610) consistently induced dose-dependent decreases in viability of isolated patient-derived CTCL cells and established CTCL cell lines (MyLa, Sez4, HH, Hut78). This effect was synergistically potentiated by combination of BET inhibition with BCL2 inhibition (e.g. venetoclax) or histone deacetylase (HDAC) inhibition (e.g. vorinostat or romidepsin). There was also a marked increase in caspase 3/7 activation when JQ1 was combined with either vorinostat or romidepsin, confirming that the observed synergies are due in major part to induction of apoptosis. Furthermore, MYC and BCL2 expression were each synergistically repre...Continue Reading

References

Mar 1, 1992·In Vitro Cellular & Developmental Biology : Journal of the Tissue Culture Association·K KaltoftK Thestrup-Pedersen
Sep 19, 1991·International Journal of Cancer. Journal International Du Cancer·G StarkebaumF W Ruscetti
Jan 1, 1991·The Journal of Investigative Dermatology·J T AbramsE DeFreitas
May 7, 2004·The New England Journal of Medicine·Michael GirardiLynn D Wilson
Jun 16, 2004·Journal of the European Academy of Dermatology and Venereology : JEADV·D V KazakovW Kempf
Feb 5, 2005·Blood·Rein WillemzeChris J L M Meijer
Apr 21, 2005·The Journal of Clinical Investigation·Ellen J KimAlain H Rook
Jul 29, 2005·The Biochemical Journal·Sujoy BhattacharyaLeonard R Johnson
May 5, 2006·Annals of Hematology·Jin Tae JungKyu Bo Lee
Sep 26, 2009·Journal of Chemical Biology·Heino Prinz
Feb 24, 2010·Nature Reviews. Molecular Cell Biology·Simona NegriniThanos D Halazonetis
Sep 28, 2010·Nature·Panagis FilippakopoulosJames E Bradner
Aug 5, 2011·Nature·Johannes ZuberChristopher R Vakoc
Sep 2, 2011·The Journal of Investigative Dermatology·William M LinMichael Girardi
Sep 6, 2011·Cell·Jake E DelmoreConstantine S Mitsiades
Sep 29, 2011·Proceedings of the National Academy of Sciences of the United States of America·Jennifer A MertzRobert J Sims
Nov 1, 2011·Molecular Cell·Fabien LlambiDouglas R Green
Apr 3, 2012·Cell·Chi V Dang
May 4, 2012·Spermatogenesis·Gurvinder Kaur, Jannette M Dufour
Nov 8, 2012·Transcription·Ballachanda N Devaiah, Dinah S Singer
Jun 21, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Emmanuella GuenovaRachael A Clark
Nov 16, 2013·Oncotarget·Anton HenssenJohannes H Schulte
Jul 1, 2014·Proceedings of the National Academy of Sciences of the United States of America·Joydeep BhaduryJonas A Nilsson
Jul 22, 2014·American Journal of Hematology·Ryan A Wilcox
Oct 14, 2014·International Journal of Cancer. Journal International Du Cancer·Dhong Hyun LeeH Phillip Koeffler
Mar 18, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ivan V LitvinovThomas S Kupper
Mar 25, 2015·Molecular Genetics & Genomic Medicine·Aleksandar SekulicTimothy K McDaniel
Jun 18, 2015·Blood·Laura Y McGirtChristine M Eischen
Jul 21, 2015·Nature Genetics·Jaehyuk ChoiRichard P Lifton

❮ Previous
Next ❯

Citations

Jan 7, 2020·Expert Review of Hematology·Nada Ahmed, Andrew L Feldman
Mar 24, 2020·Nature Reviews. Clinical Oncology·Benedito A Carneiro, Wafik S El-Deiry
Sep 7, 2019·Current Hematologic Malignancy Reports·Yuxuan LiuJennifer E Amengual
Jul 1, 2020·Expert Opinion on Investigational Drugs·Toshihisa Satta, Steven Grant
Jun 21, 2019·Medicinal Research Reviews·Daniela TomaselliAntonello Mai
Dec 17, 2019·Therapeutic Advances in Medical Oncology·Catalina Silva-HirschbergAxel H Schönthal
Jun 2, 2020·Frontiers in Oncology·Zaw H PhyoSima Rozati
May 23, 2019·Current Opinion in Hematology·Francesco Bertoni, Anastasios Stathis
Jan 2, 2021·Journal of Hematology & Oncology·Katarzyna IżykowskaGrzegorz K Przybylski
Nov 25, 2020·Bioorganic & Medicinal Chemistry Letters·Qinghua Ren, Wenqian Gao
Oct 21, 2020·European Journal of Medicinal Chemistry·Jingjing ChenYouhong Hu
Jun 15, 2020·The Journal of Investigative Dermatology·Fatima N MirzaMichael Girardi
Mar 10, 2021·Bioorganic & Medicinal Chemistry Letters·Qinghua Ren, Wenqian Gao
Apr 4, 2021·International Journal of Molecular Sciences·Walter Douglas Fairlie, Erinna F Lee
May 5, 2021·Biochimica Et Biophysica Acta. Molecular Cell Research·Gabriel PradoRichard L Bennett
Nov 19, 2021·Journal of Cellular Biochemistry·Merve KulbayJacques Bernier

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
biopsies
acetylation
Assay
PCR

Clinical Trials Mentioned

NCT01943851
NCT02964507
NCT03150056
NCT02391480

Software Mentioned

GraphPad Prism
FlowJo
Excel
SDS

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.